Related Experiment Video
Updated: Feb 2, 2026
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
18.9K
Breast Cancer and Heart Failure
Zakaria Almuwaqqat1, Jane L Meisel2, Ana Barac3
1Department of Cardiology, Emory University School of Medicine, 1364 Clifton Road, Atlanta, GA 30322, USA; Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Heart Failure Clinics
|November 20, 2018
Summary
Breast cancer treatments can cause heart failure, impacting cancer care. Early cardiovascular risk management is crucial for better patient outcomes during and after cancer therapy.
Area of Science:
- Cardiology and Oncology
- Cardio-oncology
- Cancer Therapeutics
Background:
- Shared risks and morbidities exist between heart failure and breast cancer.
- Breast cancer treatments, including chemotherapy and radiation, increase susceptibility to left ventricular dysfunction and heart failure.
- Left ventricular dysfunction can interrupt cancer treatment, limiting therapeutic options and leading to adverse outcomes.
Purpose of the Study:
- To review advances in cardiovascular care for breast cancer patients.
- To highlight challenges in managing heart failure during breast cancer treatment.
- To identify opportunities for improving cardiovascular care in contemporary breast cancer management.
Main Methods:
- Literature review of current research on breast cancer treatments and cardiovascular effects.
- Analysis of shared risks and morbidities between heart failure and breast cancer.
- Synthesis of information on cardiovascular risk management strategies.
Main Results:
- Multimodality breast cancer therapies pose risks for developing or worsening left ventricular dysfunction.
- Cardiovascular complications can necessitate treatment interruptions, negatively affecting breast cancer prognosis.
- Proactive cardiovascular risk factor management is essential throughout the cancer care continuum.
Conclusions:
- Integrated cardiovascular care is vital for patients undergoing breast cancer treatment.
- Addressing cardiovascular risks can optimize both cancer treatment delivery and patient survival.
- Further research and collaboration are needed to enhance cardio-oncology strategies.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
929
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
929
01:17Pathophysiology of Heart Failure
3.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
01:27Heart Failure I: Introduction
886
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
886
01:22Heart Failure VI: Adjunct Therapies
340
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
340
01:22Heart Failure Drugs: Diuretics
971
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
971
01:30Heart Failure V: Medical Management
319
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
319